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Abstract
Objectives:
The aim of this study was to compare the efficacy and safety of doses of fentanyl buccal tablet (FBT)
proportional to doses of opioids used for background analgesia versus dose titration starting with the
minimal dose for the management of breakthrough cancer pain (BTcP).
Methods:
A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60mg of oral
morphine equivalents and having acceptable background analgesia, were selected for a multicenter
unblinded study. Forty-one patients were randomized to receive FBT in doses proportional to the daily
opioid doses for four consecutive episodes of BTcP (group P). Forty-one patients underwent dose titration of
FBT, with an initial dose of 100 mg, for four consecutive episodes (group T). Pain intensity and symptoms
associated with opioid therapy were measured before administering any dose of FBT (T0) and 15minutes
after (T15).
Results:
In all, 80 patients were considered for analysis (39 and 41 patients in group P and T, respectively). Patients
were receiving a mean of 126 100mg of oral morphine equivalents (range 60–480mg) for background
analgesia. A total of 293 episodes of BTcP (144 and 149 in group P and T, respectively) were treated and
considered for analysis. No differences were found in the decrease of pain intensity between the two groups.
However, in patients receiving doses of oral morphine equivalents of4120mg/day, a significant number of
patients obtained a decrease in pain intensity450% in group P in comparison with group T (p¼ 0.040).
Also, the need for rescue medication was significantly more frequently reported in group T for the first
episode of BTcP (p50.0005). No differences in the level of adverse effects were observed between the two
groups. No differences in patients’ satisfaction were reported.
Conclusion:
According to the data obtained in this study, there is no evidence for the use of dose titration in the
management of BTcP in opioid-tolerant patients. Indeed, doses proportional to basal opioid regimen for
background pain seem to be effective and safe in the majority of patients. Further studies should confirm this
data in patients receiving higher doses of opioids, with other rapid-onset opioids, and in other settings.
Introduction
Breakthrough cancer pain (BTcP) has been recently defined as a transitory
increase in pain intensity that occurs either spontaneously, or in relation to a
specific predictable or unpredictable trigger, despite relatively stable and ade-
quately controlled background pain1.
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BTcP is a common problem in patients with cancer and
is associated with significant morbidity2,3. In different sur-
veys, 50–90% of cancer patients with pain have been
reported to experience intermittent flares of their pain,
although different definitions and methodologies were
used1–6.
The availability of supplemental doses of oral opioids,
in addition to the continuous analgesic medication, is the
main suggested treatment for the management of pain
flares. Given the temporal pattern of BTcP, characterized
by rapid onset and short duration, various technologies
have been developed to provide rapid onset of effect
with potent opioid drugs such fentanyl (rapid onset opi-
oids, ROOs), delivered by non-invasive routes. It has been
suggested that the therapy dose should be individually
titrated in order to adapt management of this condition
and enable effective analgesia to be delivered while min-
imizing the risk of clinically significant adverse effects1,7.
This statement has been quoted as evidence ‘‘B’’. However,
the need for titrating opioid doses in BTcP may make the
practical use of ROOs difficult in daily activity, particu-
larly at home or in outpatient clinics. Most patients may be
reluctant to try the medication and avoid the use of an
ROO, preferring, in the end, traditional oral dosing of
morphine8. Moreover, the need for dose titration with
ROOs in BTcP, has never been properly assessed and
this statement is derived from a series of papers published
for regulatory issues. To scientifically affirm the need for
titration, a randomized trial should compare a group of
patients titrated versus another group of patients who
receive proportional doses, and this study design has
never been the subject of research. For instance, there is
no evidence for dose titration as well as for using propor-
tional doses9,10. The aim of this randomized-controlled
study was to compare efficacy and safety of doses of an
ROO (fentanyl buccal tablet, FBT), given in doses propor-
tional to opioid daily doses with dose titration, starting
with the lowest dose of FBT for the management of
BTcP. The primary outcomes were the number of episodes
requiring rescue medication after the study dose and the
number of episodes with a decrease in pain intensity of
33% and 50% 15minutes after the study dose. The
secondary outcome was the number of episodes in which
patients reported adverse effects and the level of satisfac-
tion with the treatments.
Patients and methods
A multicenter prospective randomized controlled non-
blinded study was carried out in a sample of 82 cancer
patients with BTcP who were receiving strong opioids in
doses of at least 60mg of oral morphine equivalents and
had an acceptable background analgesia (4 on a numer-
ical scale from 0 to 10). Patients with more than three
episodes of BTcP/day, relevant co-existing liver or renal
disease, cognitive impairment, an expected survival less
than 3months, requiring radiotherapy, or a new course
of chemotherapy, were excluded. The study was approved
by the local ethical committee of the University of
Palermo, and adhered to Helsinki Declaration (Eudract
number 03125514, 2010). Informed consent was taken
from all patients before participation.
Randomization was computer-generated at the princi-
pal investigation center. A total of 41patients were ran-
domized to receive FBT in doses proportional to the daily
opioid doses (for example 100 mg for 60mg/day of oral mor-
phine, 200mg for 120mg/day or oral morphine, and so on)
for four consecutive episodes of BTcP (group P). A total of
41 patients underwent dose titration of FBT, with an ini-
tial dose of 100 mg. In this group, when BTcP was consid-
ered to be unsuccessfully controlled, the dose was
progressively increased for the subsequent episodes, up to
200, 400 and 800 mg, to achieve the effective dose (group
T). For each episode it was considered the percentage of
decrease in pain intensity (33% and 50%, respectively),
15minutes after administration of FBT (see below).
Age, gender, primary cancer, pain causes and mecha-
nisms on the basis of clinical history, known metastases,
physical examination, and available investigations were
recorded (particularly pain on movement due to bone
metastases). The following parameters were collected:
pain intensity, measured on a numerical rating scale
from 0 to 1011 before administering any dose of FBT
(T0) and 15minutes after (T15), symptoms associated
with opioid therapy, such as nausea and vomiting, drows-
iness, and confusion, occurring as a new event or a change
in intensity as a consequence of FBT administration,
assessed by patients, by using a scale from 0 to 3 (not at
all, slight, a lot, severe). At the end of the study, patients
were asked about their satisfaction regarding the treat-
ment, rated on a verbal scale: excellent, good, sufficient,
poor, very poor. Efficacy was assessed by differences in pain
intensity for each episode, by the number of episodes suc-
cessfully treated (decrease of33 and50% in pain inten-
sity), by the use of rescue doses, by the level of patient’s
satisfaction, and the number of patients who discontinued
the treatment for poor compliance or inefficacy. Safety was
assessed by the differences in opioids-related adverse
effects or number of patients who discontinued the treat-
ment for adverse effects.
Statistical analysis
Statistical analysis of quantitative and qualitative data,
included descriptive statistics, was performed for all the
items. Frequency analysis was performed by chi-square
test with Yates correction. The paired samples Student’s
t-test was used to compare mean pain intensity scores in
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the time periods. The two-sample Student’s t-test was used
to compare parametric variables between groups. All
p-values were two-sided and p-values less than 0.05 were
considered to indicate statistical significance. Data were
analyzed by the Epi Info software, version 3.2.2, (Centers
for Disease Control and Prevention, USA) and the SPSS
Software 14.0 version (SPSS, Inc.,Chicago, IL, USA).
Results
Patients characteristics are described in Table 1. Two
patients in group P were receiving doses of less than
60mg of oral morphine equivalents and were excluded
from the study. In all, 80 patients were considered for anal-
ysis (39 and 41 patients in group P and T, respectively).
Patients were receiving a mean of 126 100mg of oral
morphine equivalents (range 60–480mg) for background
analgesia.
A total of 293 episodes of BTcP (144 and 149 in group P
and T, respectively) were treated and considered for anal-
ysis. In all, 71 patients (36 and 35 in group P and T, respec-
tively) received the selected doses for all the four episodes
of BTcP. Five patients were excluded because they did not
present episodes of BTcP within 3 days (three and two
patients in group P and T, respectively). One of the
patients in group T was transferred to another unit. Four
patients in group T discontinued the treatment due to poor
compliance or inefficacy of the treatment and not all the
four episodes were recorded (see Figure 1).
Changes in pain intensity, number of episodes with a
decrease in pain intensity 33% and 50%, 15 minutes
after the administration of the selected dos of FBT in group
P and T are shown in Table 2. The same data in 30 patients
who were receiving oral morphine equivalents of
120mg/day are presented in Table 3. A significant
number of patients obtained a decrease in pain intensity
50% in group P in comparison with group T patients
(p¼ 0.040). The need for rescue medication was signifi-
cantly more frequently reported in group T for the first
episode of BTcP. Eight and 25 episodes in group P and
T, respectively, required a rescue dose after the selected
dose of FBT (p50.0005). This difference was less relevant
for the subsequent episodes: rescue doses were given in
seven and 11 episodes, respectively, for the second episode
of BTcP (p¼ 0.341); in six and four episodes respectively,
for the third episode of BTcP (p¼ 0.437); and in five and
one episodes respectively, for the fourth episode of BTcP
(p¼ 0.088).
No patient developed adverse effects of severe intensity
in both groups. The number of patients who developed
adverse effects of mild-to-moderate intensity, attributable
to study medication are reported in Tables 2 and 3. No
differences in adverse effects intensity was observed
between the two groups. No differences in patients’ satis-
faction were reported (p¼ 0.106, Pearson chi-square sta-
tistic test).
Discussion
Data from this study suggest that dose titration does not
add any advantage in comparison with proportional doses
in the management of BTcP, being neither more effica-
cious nor safer. Doses proportional to basal opioid regimen
for background pain are effective, providing optimal anal-
gesia in the majority of treated episodes of BTcP, and are
devoid of important adverse effects. Indeed, more patients
who underwent dose titration discontinued the treatment
for poor efficacy or compliance and required more rescue
medications after receiving FBT. As expected, patients
given similar doses of FBT of 100 mg in both arms reported
similar outcomes, because they were receiving 60mg of
oral morphine equivalents for their background analgesia.
Indeed, differences were observed in patients receiving
higher doses of oral morphine equivalents (120mg/
day), when proportional doses were higher than the initial
titration dose. This better outcome was obtained without
more adverse effects being reported. This can be explained
by the tolerance relative to opioid dose regimen. Finally,
patients’ satisfaction did not differ between the two groups.
The choice of the dose of an ROO to be prescribed for
BTcP has been controversial. Based on analysis of the lit-
erature, recent recommendations have suggested that the
dose of ROOs to be given for an episode of BTcP should be
determined by individual titration1. However, there are
several considerations regarding this statement that
should be taken into account. First, about 10–30% of epi-
sodes treated may fail during dose titration, especially in
patients receiving high doses of opioids9,10. Secondly, dose
titration may make the practical use of ROOs difficult in
the daily activity, particularly at home or in outpatient
clinics. Considering how presentation differs for each epi-
sode, titration should potentially be performed in each
case. Thirdly, using different pieces of ROO for treating
each episode may be time consuming and may well exceed
Table 1. Characteristics of patients.
Group P Group T p-value
Age (mean SD, years) 61.3(9.7) 65.4(10.5) 0.355*
Gender (M/F) 21/15 17/18 0.410y
Primary tumor
Lung 6 6
Gastrointestinal 5 10
Breast 3 3
Urogenital 8 7
Other 14 9
Incident pain due to
bone metastases
19/36 24/35 0.173y
*Two-sample t-test; yPearson chi-square statistic test with Yates
correction.
Current Medical Research & Opinion Volume 28, Number 6 June 2012
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the duration of BTcP which can subside spontaneously, as
evidenced by successful placebo-treated patients reported
in literature9. From a practical point of view, patients
should be prescribed more packages with different doses,
unless using more pieces of lower doses. Most patients may
be reluctant to try the ROO medication and avoid using
these drugs, preferring, in the end, traditional oral dosing
of morphine4. Fourthly, randomized trials that state the
need of dose titration, have never specifically examined
this issue, and the information gathered is only a
82 patients 
Group TGroup P
2 patients receiving less than 60 mg 
of oral morphine equivalents 
80 patients 
TpuorGPpuorG
stneitap14stneitap93
36 patients: 4 episodes treated 35 patients: 4 episodes treated 
3 patients: absence of episodes 2 patients: absence of episodes 
oteuddeunitnocsidstneitap4
:ecnailpmocroycacifferoop
detaertsedosipe3:stneitap2–
detaertsedosipe2:tneitap1–
detaertedosipe1:tneitap1–
Number of BTcP episodes treated and considered for comparison 
TpuorGPpuorG
941441
Figure 1. CONSORT flow chart of the study.
Table 2. Pain intensity differences between the two groups for all the
episodes of BTcP (n¼ 284).
Group P Group T p-value
T0, mean (SD) 7.6 (1.0) 8.1 (1.2)
T15, mean (SD) 3.1 (1.7)* 3.1 (1.4)*
No. of BTcP episodes
With a decrease433% 123/144 119/140 0.921y
With a decrease450% 112/144 104/140 0.490y
No. of BTcP episodesz
With AE intensity 1–2 40/144 47/140 0.289y
*p50.0005 vs. T0 (paired samples t-test); yPearson chi-square statistic
test with Yates correction; zTwo-sample t-test.
Table 3. Pain intensity differences between the two groups for episodes of
BTcP in patients receiving doses of oral morphine equivalents120mg/day
(60 and 60 episodes in groups P and T, respectively).
Group P Group T p-value
T0, mean (SD) 7.3 (0.9) 8.4 (0.9)
T15, mean (SD) 2.8 (1.6)* 3.7 (1.3)*
No. of BTcP episodes
With a decrease in PI433% 52/60 45/60 0.104y
With a decrease in PI450% 49/60 38/60 0.040y
No. of BTcP episodesz
With AE intensity 1–2 22/60 21/60 1.0y
*P50.0005 vs. T0 (paired samples t-test); yPearson chi-square statistic
test with Yates correction; zTwo-sample t-test.
Current Medical Research & Opinion Volume 28, Number 6 June 2012
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consequence of the study design which was aimed to dem-
onstrate the superiority of ROOs over placebo, oral mor-
phine or usual oral opioids, or to evaluate the safety and
efficacy of ascending doses of ROOs in dose-finding stud-
ies. The titration period was open and not confirmed by
comparison with any other method. The reason for the
lack of relationship between doses for BTcP and a basal
opioid regimen have not been clearly explained, consider-
ing that the presence of tolerance would suggest a dose
proportional to that used for background analgesia. Of
interest, tolerance to adverse effects in patients chronically
exposed to opioids has been found, despite serum fentanyl
levels as high as 6–8 ng/mL12.
Finally, despite a large interindividual variability in
patients’ dose requirements, observations from data
pooled from the same oral transmucosal fentanyl citrate
(OTFC) trials showed a statistically significant relation-
ship between the BTcP and round-the-clock opioid dose,
also considering that the protocol was not aimed at dem-
onstrating this13. When data were available, a simulation
of a calculation of doses of opioids used for background
analgesia and those achieved after individual titration
showed mean values of proportional doses very close to
those found after titration14.
It could be argued that a proportional dose without
titration could expose patients to adverse effects. In prac-
tice, although dose titration may appear safer, it requires
doses similar to those resulting from proportional doses and
may results in more failures, prolonging patients’ suffering
and reducing their compliance. In a previous small con-
trolled study comparing the use of OTFC and intravenous
morphine given at doses proportional to the daily opioid
dosage15, both intravenous morphine and OTFC were
effective without producing relevant adverse effects,
even when started at high doses in highly tolerant patients.
In a study reproducing a clinical scenario of patients
receiving opioids for BTcP, the dose of oral opioids used
as rescue medication was 18% of the round-the-clock
opioid dose, whereas for OTFC, titrated to determine the
effective dose, the rescue dose was about 35% of the round-
the-clock dose16, suggesting that the titration process may
provide even higher doses than those expected by using
proportional doses to the basal regimen.
Preliminary and confirmatory surveys have shown the
safety of this approach in a large number of patients with
no life-threatening adverse effects which occurs even in
older patients treated with large doses of intravenous mor-
phine. Respiratory depression, which is the most feared
adverse effect, has never occurred, and no emergency
call was needed17–19. As intravenous morphine has the
highest intrinsic risk for serious adverse events, one
could argue that other drugs with similar rapid effects
should be at least as safe. On the other hand experience
is quite limited in patients receiving high doses of opioids.
All the studies were based on limited maximum doses of
the different ROOs (OTFC, FBT, intranasal fentanyl and
sublingual fentanyl, 1600, 800, 200, and 800 mg, respec-
tively. For instance, in a recent preliminary study of the
use of FBT in patients receiving high doses of opioids,
proportionally higher doses of FBT were effective and
well-tolerated by most patients20. This can be explained
by the protective effect offered by opioid tolerance in
patients chronically receiving relevant opioid doses for
the management of cancer pain.
Among the ROOs available at the time of planning the
current study, FBT was chosen because of its availability,
greater independence from variability associated with the
individual use, for example that found with OTFC. The
interval of 15minutes was chosen to evaluate the effec-
tiveness of the treatment, as FBT is expected to produce
analgesia within this period21.
The principal limitation of this study is the lack of
blindness. Regardless of this, the complexity of this proce-
dure in this context, and the associated costs for a study
which was spontaneous and not sponsored must be borne
in mind. In the same way as the current study design, all
titration phases reported in the literature were open and
not controlled, as were other studies assessing the efficacy
and the safety of opioids given in doses proportional to the
opioid basal regimen17–19. These experiences have shown
that in patients receiving opioids for chronic cancer pain
the risks of administering about 20% of the daily dose of
opioids with rapid modalities, intravenously or transmuco-
sally, are minimal, going back to previous recommenda-
tions of European Association for Palliative Care, based on
clinical experience22. The sample of patients was typical in
terms of opioid treatment for background analgesia, rang-
ing from 60 to 480mg of oral morphine equivalents.
It is likely that differences could be more relevant in a
selected population of patients receiving high doses of opi-
oids, as suggested by data of patients receiving 120mg/
daily of oral morphine equivalents.
In conclusion, a titration process starting with the
lowest doses of FBT, does not add any advantage in com-
parison with proportional doses in the management of
BTcP, being neither more efficacious or safer. Doses pro-
portional to basal opioid regimen for background pain
seem to be effective and safe in the majority of patients.
From a practical perspective, to reduce patients’ reluctance
in asking for opioid rescue medication8,16,23, a definite
indication should be provided and self-titration is unlikely
to be accepted, unless performed in an assisted setting.
Practical problems, including the need of titration, has
probably limited the use of ROOs, despite the superiority
over oral opioids and placebo demonstrated in various
studies, regardless of the cost. As a consequence many
patients will continue to prefer the conventional use of
oral morphine, even thoughmost of the episodes will evan-
ish spontaneously8, and an uneventful burst of morphine
will be gratuitously given. It is also to underline that all the
Current Medical Research & Opinion Volume 28, Number 6 June 2012
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pioneer controlled studies were designed for approval from
FDA. Therefore, indications were dictated by the pru-
dence of managing new delivery systems, which were in
their infancy. Further studies should be performed to con-
firm the data with other delivery systems, selected popu-
lation, such as elderly, or patients receiving high doses of
opioids for chronic cancer pain.
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